Page last updated: 2024-12-06

metomidate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Metomidate is a synthetic imidazole derivative that acts as a non-competitive antagonist of the NMDA receptor. It has been investigated for its potential therapeutic effects in conditions like epilepsy and stroke. Its mechanism of action involves blocking the influx of calcium ions through the NMDA receptor channel, which is crucial for neuronal signaling and plasticity. Metomidate has shown promising preclinical results in reducing seizure activity and promoting neuroprotection in animal models. However, it has not yet been approved for clinical use due to concerns about its safety profile, including potential cardiovascular effects and neurotoxicity.'

metomidate: was heading 1975-94 (see under IMIDAZOLES 1975-90); METHOXIMOL was see METOMIDATE 1975-94; use IMIDAZOLES to search METOMIDATE 1975-94; a hypnotic and sedative that may also function as an anesthetic; now banned as an anesthetic for swine; C11-metomidate used as tracer for PET for adrenal neoplasms [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID21474
CHEMBL ID494039
CHEBI ID188672
SCHEMBL ID491910
MeSH IDM0224678

Synonyms (65)

Synonym
metomidate [inn:ban]
imidazole-5-carboxylic acid, 1-(alpha-methylbenzyl)-, methyl ester
1h-imidazole-5-carboxylic acid, 1-(1-phenylethyl)-, methyl ester
r 7315
metomidato [inn-spanish]
methyl 1-(alpha-methylbenzyl)imidazole-5-carboxylate
metomidate
methoxymol r7315
brn 0659586
hypnodil
methoximol
einecs 226-368-4
r-7315
metomidatum [inn-latin]
methoxymol
TIMTEC1_008449
3-(1-phenyl-ethyl)-3h-imidazole-4-carboxylic acid methyl ester
methyl 1-(1-phenylethyl)-1h-imidazole-5-carboxylate
STK331722
HMS1558A01
5377-20-8
metomidate (inn)
D08210
AKOS000548918
CHEMBL494039
CHEBI:188672
methomidate
methyl 3-(1-phenylethyl)imidazole-4-carboxylate
NCGC00073457-03
NCGC00073457-02
NCGC00087871-02
unii-z18zyl8y51
z18zyl8y51 ,
aquacalm
metomidatum
metomidato
methoxymol r-7315
FT-0672378
AKOS021997987
metomidate [inn]
metomidate [mi]
(+/-)-metomidate
etomidate impurity, metomidate- [usp impurity]
etomidate impurity b [ep impurity]
methyl 1-(.alpha.-methylbenzyl)imidazole-5-carboxylate
DTXSID1048411 ,
SCHEMBL491910
FHFZEKYDSVTYLL-UHFFFAOYSA-N
methyl 1-(1-phenylethyl)-1h-imidazole-5-carboxylate #
imidazole-5-carboxylic acid, 1-(.alpha.-methylbenzyl)-, methyl ester
AC-24333
etomidate ep impurity b
Q6824219
BCP12851
r 7315; r-7315; r7315;aquacalm;hypnodil;11c-metomidate
AMY38877
A853168
A899815
etomidate impurity b
F78045
metomidato (inn-spanish)
dtxcid9028384
etomidate impurity b (ep impurity)
etomidate impurity, metomidate-(usp impurity)
metomidatum (inn-latin)

Research Excerpts

Overview

C-metomidate (MTO) is a tracer used in PET that provides functional information about the adrenal cortex. Metomidate hydrochloride is an imidazole-based, nonbarbiturate hypnotic drug.

ExcerptReferenceRelevance
"11 C-metomidate (MTO) is a tracer used in PET that provides functional information about the adrenal cortex."( Predicting Treatment Response in Primary Aldosteronism Using 11 C-Metomidate Positron Emission Tomography.
Chang, CC; Chen, CJ; Chueh, JS; Lu, CC; Peng, KY; Wu, VC; Yen, RF, 2022
)
1.41
"Metomidate hydrochloride is an imidazole-based, nonbarbiturate hypnotic drug primarily used as an immersion sedation and anesthetic agent in freshwater and marine finfish. "( Evaluation of metomidate hydrochloride as an anesthetic in leopard frogs (Rana pipiens).
da Cunha, AF; Doss, GA; Fowlkes, N; Nevarez, JG, 2014
)
2.21

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic modeling of the data showed that metomidate had shorter elimination half-life and higher plasma concentrations in turbot compared with halibut, both species displaying a rapid uptake, distribution and excretion."( Pharmacokinetic and pharmacodynamic properties of metomidate in turbot (Scophthalmus maximus) and halibut (Hippoglossus hippoglossus).
Hansen, MK; Horsberg, TE; Nymoen, U, 2003
)
0.83
"Early, intermediate and late pharmacokinetic phases could be isolated in this manner."( Masked volume wise Principal Component Analysis of small adrenocortical tumours in dynamic [11C]-metomidate Positron Emission Tomography.
Hellman, P; Hennings, J; Långström, B; Monazzam, A; Razifar, P; Sundin, A, 2009
)
0.57

Bioavailability

ExcerptReferenceRelevance
" The oral bioavailability (F) was calculated to 100% in turbot."( Pharmacokinetic and pharmacodynamic properties of metomidate in turbot (Scophthalmus maximus) and halibut (Hippoglossus hippoglossus).
Hansen, MK; Horsberg, TE; Nymoen, U, 2003
)
0.57

Dosage Studied

ExcerptRelevanceReference
" Further studies are needed to provide additional data for these and other species and families, for different water chemistry conditions, and for various biological factors to fine-tune dosing regimens."( Preliminary Investigations into Use of Metomidate for Euthanasia of Ornamental Fishes.
Yanong, RPE, 2021
)
0.89
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
imidazolesA five-membered organic heterocycle containing two nitrogen atoms at positions 1 and 3, or any of its derivatives; compounds containing an imidazole skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID360466Octanol-water partition coefficient, log KOW of the compound2007The Journal of biological chemistry, Apr-20, Volume: 282, Issue:16
Identification of anesthetic binding sites on human serum albumin using a novel etomidate photolabel.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (59)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's6 (10.17)18.2507
2000's16 (27.12)29.6817
2010's25 (42.37)24.3611
2020's12 (20.34)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 36.39

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index36.39 (24.57)
Research Supply Index4.28 (2.92)
Research Growth Index4.87 (4.65)
Search Engine Demand Index49.01 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (36.39)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials9 (14.52%)5.53%
Reviews5 (8.06%)6.00%
Case Studies3 (4.84%)4.05%
Observational0 (0.00%)0.25%
Other45 (72.58%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Primary Aldosteronism and Surgically Curable Forms in Hypertension Patients Using 11C-Metomidate [NCT03990701]Early Phase 125 participants (Actual)Interventional2018-05-21Completed
11C-Metomidate PET/CT for Endocrine Hypertension and Characterisation of Adrenal Tumours [NCT06100367]Phase 2/Phase 3100 participants (Anticipated)Interventional2019-12-30Recruiting
Functional Imaging With 11C-Metomidate Positron Emission Tomography Versus Adrenal Vein Sampling in Differential Diagnosis of Unilateral and Bilateral Aldosterone Secretion in Primary Aldosteronism [NCT01567111]40 participants (Anticipated)Interventional2012-02-29Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]